<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878396</url>
  </required_header>
  <id_info>
    <org_study_id>IOV2011/35</org_study_id>
    <secondary_id>CE IOV 2011/35</secondary_id>
    <nct_id>NCT01878396</nct_id>
  </id_info>
  <brief_title>Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors</brief_title>
  <acronym>CMCBRAF</acronym>
  <official_title>Predictive Value of Circulating Melanoma Cells (CMCs) in Metastatic Melanoma (MM) Patients Treated With Selective Inhibitors of BRAF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Diagnostics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study, is to evaluate Circulating Melanoma Cell (CMC) changes in
      Metastatic Melanoma (MM) patients, undergoing treatment with selective inhibitors of mutated
      BRAF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational prospective pilot study aimed to investigate the association between
      changes of total and apoptotic CMC count and disease progression in MM patients undergoing
      treatment with selective inhibitors of mutated B-RAF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of CMC count during treatment and comparison with CT and PET</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Mutated Anti-B-RAF</arm_group_label>
    <description>Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-B-RAF</intervention_name>
    <arm_group_label>Mutated Anti-B-RAF</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fourth stage Melanoma patients with both measurable and not measurable lesions
             undergoing treatment with selective B-RAF inhibitors will be included. To determine
             the prevalence of CMC-positive patients in IV stage Melanoma, patients without mutated
             B-RAF undergoing chemotherapy and/or vaccines will be also enrolled at baseline, as
             part of study protocols approved and activated in the participating centers.

          -  Informed written consent.

        Exclusion Criteria:

          -  Inadequate compliance to multiple blood draws (baseline, 15 days, 1th month, 4th
             month, and/or at progression) as scheduled in this adjunctive biologic study for
             patients carrying B-FAF mutation; inadequate compliance to adjunctive blood draws, as
             scheduled at baseline for BRAF wild-type

          -  Previously exposure to immunological treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Zanovello, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Padua University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanna Chiarion-Sileni, MD</last_name>
    <phone>0039 0498215931</phone>
    <email>mgaliz@tiscali.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rita Zamarchi, MD</last_name>
    <phone>0039 0498215873</phone>
    <email>rita.zamarchi@unipd.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanna Chiarion-Sileni, MD</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanna Chiarion-Sileni, MD</last_name>
      <phone>0039 0498215931</phone>
      <email>mgaliz@tiscali.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, Clack G, Malone M, Coumans FA, Terstappen LW. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011 Mar;38(3):755-60. doi: 10.3892/ijo.2011.896. Epub 2011 Jan 3.</citation>
    <PMID>21206975</PMID>
  </reference>
  <reference>
    <citation>Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res. 2006 Aug 1;12(15):4605-13.</citation>
    <PMID>16899608</PMID>
  </reference>
  <reference>
    <citation>Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, Bonciarelli G, Tumolo S, Ghiotto C, Magro C, Jirillo A, Indraccolo S, Amadori A, Zamarchi R. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res. 2010 Nov 1;16(21):5233-43. doi: 10.1158/1078-0432.CCR-10-1449. Epub 2010 Oct 26.</citation>
    <PMID>20978147</PMID>
  </reference>
  <reference>
    <citation>Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristofanilli M, Amadori A, Zamarchi R. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer. 2012 Oct 9;107(8):1286-94. doi: 10.1038/bjc.2012.388. Epub 2012 Sep 6.</citation>
    <PMID>22955853</PMID>
  </reference>
  <reference>
    <citation>Mocellin S, Del Fiore P, Guarnieri L, Scalerta R, Foletto M, Chiarion V, Pilati P, Nitti D, Lise M, Rossi CR. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 2004 Sep 20;111(5):741-5.</citation>
    <PMID>15252844</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>September 30, 2016</last_update_submitted>
  <last_update_submitted_qc>September 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating Melanoma cells in metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

